Health Care & Life Sciences » Pharmaceuticals | Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Dicerna Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
iShares Russell 2000 ETF
929,508
1.76%
-495
0.03%
09/06/2018
Fidelity Select Biotechnology Portfolio
914,926
1.73%
-872
0.16%
07/31/2018
Vanguard Total Stock Market Index Fund
826,354
1.56%
0
0%
07/31/2018
iShares Russell 2000 Growth ETF
432,395
0.82%
0
0.06%
09/06/2018
Vanguard Extended Market Index Fund
320,401
0.61%
3,005
0.01%
07/31/2018
Fidelity OTC Portfolio
307,207
0.57%
0
0.02%
07/31/2018
Emerald Growth Fund
195,763
0.37%
195,763
0.22%
04/30/2018
Bridgeway Ultra Small Company Market Fund
141,600
0.27%
-18,400
0.52%
12/31/2017
Fidelity Advisor Biotechnology Fund
124,565
0.24%
-77,741
0.07%
07/31/2018
iShares Micro Cap ETF
119,064
0.23%
0
0.17%
09/06/2018

About Dicerna Pharmaceuticals

View Profile
Address
87 Cambridgepark Drive
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.dicerna.com
Updated 07/08/2019
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.